Ascentage Pharma (HKG:6855) presented the results of five preclinical studies at the meeting of the American Association for Cancer Research in Chicago, according to a Monday filing with the Hong Kong bourse.

The presentations, in poster form, are for its olverembatinib and lisaftoclax drugs for acute myeloid leukemia, as well as APG-5918 for prostate cancer, APG-2449 for small-cell lung cancer, and AS03157 for apoptosis protein inhibition or cell death prevention, the filing said.